FDA 483 - Catalent Maryland, Inc. - April 09, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Catalent Maryland, Inc. in Baltimore, MD, a biological drug product manufacturer, revealed two significant observations. The firm failed to follow procedures designed to prevent microbiological contamination during sterile filling operations and did not maintain its manufacturing buildings in a good state of repair, specifically noting floor damage in a critical area. These issues indicate potential risks to the sterility and quality of drug products.
ID · 6364cf7a-9c9e-4c45-91b6-3878217bd57b